116 related articles for article (PubMed ID: 8414680)
21. In vitro susceptibility of yeasts isolated from patients in intensive care units to fluconazole and amphotericin B during a 3-year period.
Kucukates E; Erturan Z; Susever S; Yegenoglu Y
APMIS; 2005 Apr; 113(4):278-83. PubMed ID: 15865609
[TBL] [Abstract][Full Text] [Related]
22. [Disk diffusion method for fluconazole susceptibility testing of Candida spp. isolates].
Rodero L; Córdoba S; Vivot W; Campo M; Corfield P; Olguín C; Cuirolo A; Soria M; Guelfand L; Canteros CE; Davel G;
Rev Argent Microbiol; 2006; 38(3):155-63. PubMed ID: 17152217
[TBL] [Abstract][Full Text] [Related]
23. [The value of the agar dilution method as a screening test for determining the sensitivity of Candida albicans to fluconazole].
Yücesoy M; Marol S
Mikrobiyol Bul; 2002; 36(3-4):317-22. PubMed ID: 12838666
[TBL] [Abstract][Full Text] [Related]
24. Rapid identification of fluconazole resistance using Chrom agar Candida.
Verghese SL; Padmaja P; Sutha P; Mathew T; Johni ES
Indian J Pathol Microbiol; 2001 Jul; 44(3):305-7. PubMed ID: 12024918
[TBL] [Abstract][Full Text] [Related]
25. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.
Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Meis JF; Gould IM; Fu W; Colombo AL; Rodriguez-Noriega E;
J Clin Microbiol; 2007 Jun; 45(6):1735-45. PubMed ID: 17442797
[TBL] [Abstract][Full Text] [Related]
26. In vitro susceptibilities to yeasts using the ATB FUNGUS 2 method, compared with Sensititre Yeast One and standard CLSI (NCCLS) M27-A2 methods.
Torres-Rodríguez JM; Alvarado-Ramírez E
J Antimicrob Chemother; 2007 Sep; 60(3):658-61. PubMed ID: 17623690
[TBL] [Abstract][Full Text] [Related]
27. [Susceptibility testing of fluconazole: evaluation of a multicenter study of the working group "Clinical Mycology" of the German Speaking Mycological Society].
Schmalreck AF
Mycoses; 1996; 39 Suppl 2():1-11. PubMed ID: 9198736
[TBL] [Abstract][Full Text] [Related]
28. [The in vitro antifungal activities of fluconazole against pathogenic yeasts recently isolated from clinical specimens].
Yamaguchi H; Igari J; Kume H; Abe M; Oguri T; Kanno H; Kawakami S; Okuzumi K; Fukayama M; Ito A; Kawata K; Uchida K
Jpn J Antibiot; 1997 Sep; 50(9):799-805. PubMed ID: 9394240
[TBL] [Abstract][Full Text] [Related]
29. Effect of culture media on in vitro susceptibility testing of fluconazole against some yeasts.
Sekhon AS; Garg AK; Hamir Z
Mycoses; 1991; 34(7-8):319-22. PubMed ID: 1803235
[TBL] [Abstract][Full Text] [Related]
30. [Laboratory's controls of antifungal treatment by the fluconazole of the candidiasis in immunocompromised patients].
Blancard A; Moulin-Traffort J; Regli P; Sarzier JM; Quilici M
Pathol Biol (Paris); 1991 May; 39(5):534-8. PubMed ID: 1881690
[TBL] [Abstract][Full Text] [Related]
31. Modified agar dilution susceptibility testing method for determining in vitro activities of antifungal agents, including azole compounds.
Yoshida T; Jono K; Okonogi K
Antimicrob Agents Chemother; 1997 Jun; 41(6):1349-51. PubMed ID: 9174197
[TBL] [Abstract][Full Text] [Related]
32. Enhanced activity of antifungal drugs using natural phenolics against yeast strains of Candida and Cryptococcus.
Faria NC; Kim JH; Gonçalves LA; Martins Mde L; Chan KL; Campbell BC
Lett Appl Microbiol; 2011 May; 52(5):506-13. PubMed ID: 21332761
[TBL] [Abstract][Full Text] [Related]
33. The Celecoxib Derivative AR-12 Has Broad-Spectrum Antifungal Activity In Vitro and Improves the Activity of Fluconazole in a Murine Model of Cryptococcosis.
Koselny K; Green J; DiDone L; Halterman JP; Fothergill AW; Wiederhold NP; Patterson TF; Cushion MT; Rappelye C; Wellington M; Krysan DJ
Antimicrob Agents Chemother; 2016 Dec; 60(12):7115-7127. PubMed ID: 27645246
[TBL] [Abstract][Full Text] [Related]
34. In vitro anti-yeast activity of chloramphenicol: A preliminary report.
Joseph MR; Al-Hakami AM; Assiry MM; Jamil AS; Assiry AM; Shaker MA; Hamid ME
J Mycol Med; 2015 Mar; 25(1):17-22. PubMed ID: 25497707
[TBL] [Abstract][Full Text] [Related]
35. [A comparative study between broth dilution and agar dilution technics in antibiograms for Candida].
Alves SH; Cury AE
Rev Inst Med Trop Sao Paulo; 1992; 34(3):259-62. PubMed ID: 1342081
[TBL] [Abstract][Full Text] [Related]
36. Susceptibility of Candida albicans and other yeasts to fluconazole: relation between in vitro and in vivo studies.
Galgiani JN
Rev Infect Dis; 1990; 12 Suppl 3():S272-5. PubMed ID: 2184504
[TBL] [Abstract][Full Text] [Related]
37. [Effect of the cultivation conditions of Candida species yeast-like fungi on their sensitivity to levorin].
Vasil'eva NG; Fradkova TA; Golubkova LS
Antibiotiki; 1977 May; 22(5):433-7. PubMed ID: 327914
[TBL] [Abstract][Full Text] [Related]
38. Antifungal activity of the honeybee products against Candida spp. and Trichosporon spp.
Koç AN; Silici S; Kasap F; Hörmet-Oz HT; Mavus-Buldu H; Ercal BD
J Med Food; 2011; 14(1-2):128-34. PubMed ID: 21128826
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of artemisinin derivative artemether as a fluconazole potentiator through inhibition of Pdr5.
Zhou J; Li J; Cheong I; Liu NN; Wang H
Bioorg Med Chem; 2021 Aug; 44():116293. PubMed ID: 34243044
[TBL] [Abstract][Full Text] [Related]
40. Cryptococcus neoformans Yap1 is required for normal fluconazole and oxidative stress resistance.
Paul S; Doering TL; Moye-Rowley WS
Fungal Genet Biol; 2015 Jan; 74():1-9. PubMed ID: 25445311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
